• 1
    Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001; 34: 12251241.
  • 2
    Liaw YF, Leung N, Guan R, Lau GK, Merican I. Asia Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003; 18: 239245.
  • 3
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168174.
  • 4
    Evans AA, O'Connell AP, Pugh JC, Mason WS, Shen FM, Chen GC, et al. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998; 7: 559565.
  • 5
    Ohkubo K, Kato Y, Ichikawa T, Kajiya Y, Takeda Y, Higashi S, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002; 94: 26632668.
  • 6
    De Jongh FE, Janssen HLA, De Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 16301635.
  • 7
    Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294298.
  • 8
    Liaw YF, Sung JJ, Wan CC, Shue K, Keene O, Farrell G. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial [Abstract]. HEPATOLOGY 2003; 38(4 Suppl 1 ): 262A.
  • 9
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312323.
  • 10
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 6168.
  • 11
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808816.
  • 12
    Niederau C, Heintges T, Lange S Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14221427.
  • 13
    Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 2001; 34: 785791.
  • 14
    Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687696.
  • 15
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2001; 33: 15271532.
  • 16
    Locarnini S. Clinical relevance of viral dynamics and genotypes in hepatitis B virus. J Gastroenterol Hepatol 2002; 17( Suppl 3): S322S328.
  • 17
    Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180: 17571762.
  • 18
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292297.
  • 19
    Yang H, Westland C, Delaney IVWE, Angus PW, Locarnini SA, Kitis G, et al. Complete genotypic and phenotypic analyses of HBV mutations identified in HBeAg-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV) [Abstract]. HEPATOLOGY 2003; 38(4 Suppl 1 ): 705A.
  • 20
    Bartholomeusz A, Locarnini S, Ayres A, Thompson G, Edwards R, Colledge D, et al. Molecular modeling and functional studies of adefovir resistant mutations in the hepatitis B virus polymerase selected during therapy [Abstract]. HEPATOLOGY 2003; 38: 273A
  • 21
    Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral β-L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45: 229235.
  • 22
    Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral β-L-nucleosides specific for hepatitis B virus infection. Antiviral Chemistry Chemother 2001; 12( Suppl 1): 119129.
  • 23
    Ross EM. Pharmacodynamics. Mechanisms of drug action and the relationship between drug concentration and effect. In: HardmanJG, LimbirdLE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition. New York: McGraw-Hill, 1996: 2941.
  • 24
    Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinetics 1999; 36: 4166.
  • 25
    Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46: 17341740.
  • 26
    Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002; 22: 121126.
  • 27
    Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. HEPATOLOGY 1999; 29: 18631869.
  • 28
    Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37: 137144 [erratum: J Hepatol 2002;37:708].
  • 29
    Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93: 43984402.
  • 30
    Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 18311838.
  • 31
    Honkoop P, de Man RA, Niesters HG, Main J, Nevens F, Thomas HC, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepatitis 1998; 5: 307312.